ACP
KTTA icon

Acuta Capital Partners’s Pasithea Therapeutics KTTA Stock Holding History

Acuta Capital Partners’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-450,000
Closed -$581K – 33
2025
Q4 		$581K Buy
+450,000
New +$395K 0.39% 28

Other funds holding KTTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acuta Capital Partners's KTTA Position: Q1 2026 in Review

Acuta Capital Partners sold out of Pasithea Therapeutics (KTTA) in Q1 2026, closing a stake of 450,000 shares — an estimated $581K sold.

Acuta Capital Partners first reported a position in KTTA in Q4 2025 and held it in 1 quarter. The position peaked at $581K in Q4 2025. 21 funds tracked by Wall St. Rank hold KTTA as of Q1 2026.

  • Acuta Capital Partners reported no remaining Pasithea Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Acuta Capital Partners sold 450,000 Pasithea Therapeutics shares in Q1 2026, an estimated $581K.
  • Acuta Capital Partners first reported a position in Pasithea Therapeutics in Q4 2025 and held it in 1 quarter.
  • Acuta Capital Partners's Pasithea Therapeutics position peaked at $581K in Q4 2025.
  • 21 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q1 2026.

Based on Acuta Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.